CINECA IRIS Institutional Research Information System

VIOLA, DAVID
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.479
EU - Europa 3.871
AS - Asia 3.239
SA - Sud America 499
AF - Africa 232
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 3
Totale 14.333
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.307
DE - Germania 1.329
SG - Singapore 1.031
CN - Cina 953
IT - Italia 726
HK - Hong Kong 596
SE - Svezia 565
BR - Brasile 399
GB - Regno Unito 380
BG - Bulgaria 235
VN - Vietnam 181
AT - Austria 157
RU - Federazione Russa 144
TR - Turchia 125
CA - Canada 124
CI - Costa d'Avorio 119
IN - India 94
FI - Finlandia 93
FR - Francia 61
JP - Giappone 57
SN - Senegal 55
BD - Bangladesh 41
AR - Argentina 37
KR - Corea 32
PL - Polonia 26
UA - Ucraina 26
NL - Olanda 21
MX - Messico 20
IQ - Iraq 19
ZA - Sudafrica 19
BE - Belgio 17
EC - Ecuador 17
ES - Italia 15
MA - Marocco 15
SA - Arabia Saudita 14
CH - Svizzera 13
CO - Colombia 11
ID - Indonesia 11
IR - Iran 11
LT - Lituania 11
PK - Pakistan 11
UY - Uruguay 10
UZ - Uzbekistan 10
IE - Irlanda 9
AU - Australia 8
GR - Grecia 7
PH - Filippine 7
VE - Venezuela 7
CL - Cile 6
TN - Tunisia 6
HU - Ungheria 5
PY - Paraguay 5
SK - Slovacchia (Repubblica Slovacca) 5
AZ - Azerbaigian 4
BO - Bolivia 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
EG - Egitto 4
IL - Israele 4
JO - Giordania 4
MY - Malesia 4
NG - Nigeria 4
PA - Panama 4
PT - Portogallo 4
AE - Emirati Arabi Uniti 3
EE - Estonia 3
GA - Gabon 3
HN - Honduras 3
JM - Giamaica 3
KE - Kenya 3
KZ - Kazakistan 3
LK - Sri Lanka 3
NP - Nepal 3
RO - Romania 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AL - Albania 2
AO - Angola 2
BH - Bahrain 2
BY - Bielorussia 2
BZ - Belize 2
CR - Costa Rica 2
CY - Cipro 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EU - Europa 2
LB - Libano 2
MN - Mongolia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PE - Perù 2
PR - Porto Rico 2
A1 - Anonimo 1
BS - Bahamas 1
DM - Dominica 1
GT - Guatemala 1
HR - Croazia 1
KG - Kirghizistan 1
KN - Saint Kitts e Nevis 1
Totale 14.325
Salva come PNG Salva come JPEG
Città #
Ashburn 780
Hong Kong 583
Singapore 530
Woodbridge 508
Chandler 506
Fairfield 447
Dallas 437
Santa Clara 405
Houston 351
Ann Arbor 267
Sofia 235
Shanghai 233
Beijing 221
Seattle 220
Milan 211
Wilmington 206
New York 189
Cambridge 161
Vienna 139
Princeton 131
London 123
Abidjan 119
Los Angeles 117
Boardman 109
Lawrence 95
Munich 88
Ottawa 79
Medford 75
Florence 62
Serra 60
Boulder 58
Des Moines 58
Dakar 55
Frankfurt am Main 51
Izmir 48
Dearborn 46
Istanbul 45
Nanjing 44
Redondo Beach 43
Tokyo 43
Bremen 40
Hefei 40
Pisa 39
Rome 38
Dong Ket 36
Ho Chi Minh City 35
São Paulo 34
San Diego 33
Buffalo 32
Nürnberg 26
Seoul 25
Fuzhou 22
Turku 22
Düsseldorf 20
Belo Horizonte 19
Council Bluffs 19
Helsinki 18
Redwood City 17
Brussels 16
Changsha 16
Columbus 16
Hanoi 16
Jacksonville 16
Quanzhou 16
Guangzhou 15
Lancaster 15
Montreal 15
Redmond 15
Zhengzhou 15
Ogden 14
Washington 14
Denver 13
Jiaxing 13
Rio de Janeiro 13
Dhaka 12
Nanchang 12
Orem 12
Phoenix 12
Toronto 12
Johannesburg 11
Kunming 11
Norwalk 11
San Francisco 11
Tianjin 11
Warsaw 11
Ankara 10
Brasília 10
Chengdu 10
Chicago 10
San Jose 10
Shenyang 10
Stockholm 10
Wuhan 10
Atlanta 9
Jinan 9
Philadelphia 9
Tashkent 9
Dublin 8
Lucca 8
Riyadh 8
Totale 9.197
Salva come PNG Salva come JPEG
Nome #
Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy 308
null 259
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 236
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 224
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 221
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 214
Targeted Therapy in Thyroid Cancer: State of the Art 210
Incidental versus clinically evident thyroid cancer: A 5-year follow-up study 206
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 206
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 200
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 200
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 198
Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years. 191
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study 189
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 188
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 186
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 184
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 184
DIAGNOSTIC AND THERAPEUTIC ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 182
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 179
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 173
Il carcinoma tiroideo: nuove prospettive terapeutiche. 172
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 172
BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. 167
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer 163
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 163
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 162
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 159
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 158
Role Of Prophylactic Central Compartment Lymph Node Dissection On The Outcome Of Patients With Papillary Thyroid Carcinoma And Synchronous Ipsilateral Cervical Lymph Node Metastases 158
Role of YAP-1 in Thyroid Tumor Progression and Outcome 157
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 157
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 154
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 153
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 152
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 152
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 152
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 151
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 151
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 151
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 151
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 148
null 146
Tall cell percentage alone in PTC without aggressive features should not guide patients’ clinical management 146
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 145
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 145
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 143
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 141
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 141
Papillary Thyroid Carcinoma With Rare exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience 139
An idic(15) associated with POF (premature ovarian failure): Molecular cytogenetic definition of a case and review of the literature. 136
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 135
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 135
Infertility in a patient with papillary thyroid carcinoma treated with high doses of 131-I. 134
Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer 134
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 133
Medullary thyroid carcinoma in children 131
BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid cancer 131
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 128
Cabozantinib: An orphan drug for thyroid cancer 127
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 123
Management of Medullary Thyroid Cancer 122
BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment 119
Protocolli gestionali-diagnostico-terapeutico-assistenziali in chirurgica tiroidea. 2° Consensus Conference. 118
The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer 118
BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma 116
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 115
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 114
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 114
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 113
Proteinuria is a late-onset adverse event in patients treated with cabozantinib 112
La tiroide come sede di metastasi 111
null 110
BRAFV600E mutation is an indipendent bad prognostic factor for the out come of patients with papillary thyroid carcinoma: a 15-year median follow-up study. 110
Short term follow-up outcome of stage I thyroid cancer patients is worst when BRAFV600E mutation is present in the primary tumor. 108
null 107
null 105
The Integrity of Tumor Capsule Identifies a Subgroup of Indolent Cases Not Only Among the Follicular (FVPTC) But Also in Classic Variant of Papillary Thyroid Cancer (CVPTC) 105
Targeted therapies for thyroid cancer. 102
Follicular (FVPTC) VS Classical (CVPTC) variant of papillary thyroid cancer: correlation of the outcome after 12 years of follow up. 102
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study 100
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 100
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 98
. Utilità della ricerca della mutazione di BRAF nel tumore primitivo di pazienti affetti da carcinoma papillare della tiroide a basso rischio. 97
BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer 97
KIF5B/RET rearrangement in diffuse sclerosing variant of papillary thyroid cancer (DSV-PTC) 87
null 86
null 86
null 84
Biological and molecular markers for diagnosis, follow-up and prognosis of patients affected by thyroid cancer. 83
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. 80
null 79
Incidental versus clinically evident thyroid cancer: A 5-year follow-up study. 71
Ret Oncogene and Thyroid Carcinoma 68
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. 68
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer 67
Long Term Outcomes of Patients Undergoing Ablation With Low Activities of RAI. 66
BRAF(V600E) mutations are correlated with a lower expression of both NIS and TPO mRNA expression in papillary thyroid cancer (PTC) 65
How to manage patients with differentiated thyroid cancer and a rising serum thyroglobulin level. 62
New insights in the management of differentiated thyroid cancer. 61
Totale 13.960
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.108
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.108
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021472 0 0 0 0 0 85 60 44 62 62 31 128
2021/20221.101 26 39 22 62 229 159 33 46 59 46 77 303
2022/20231.835 207 310 154 150 163 201 35 138 333 13 118 13
2023/20241.022 116 104 124 69 132 198 64 19 17 18 53 108
2024/20253.298 38 134 40 184 365 294 226 148 387 463 296 723
2025/20262.270 325 504 417 341 418 265 0 0 0 0 0 0
Totale 14.548